Background

Autologous blood products, such as platelet-rich plasma (PRP) are commercial products broadly used to accelerate healing of tissues after injuries. However, their content is not standardized and significantly varies in composition, which may lead to differences in clinical efficacy. Also, the underlying molecular mechanisms for therapeutic effects are not well understood.

Purpose

A proteomic study was performed to compare the composition of low leukocyte PRP, platelet poor plasma (PPP), and blood plasma. Pathway analysis of the proteomic data was performed to evaluate differences between plasma formulations at the molecular level. Low abundance regulatory proteins in plasma were identified and quantified as well as cellular pathways regulated by those proteins.

Methods

Quantitative proteomic analysis, using multiplexed isotopically labeled tags (TMT labeling) and label-free tandem mass spectrometry, was performed on plasma, low leukocyte PRP, and PPP. Plasma formulations were derived from two blood donors (one donor per experiment). Pathway analysis of the proteomic data identified the major differences between formulations.

Results

Nearly 600 proteins were detected in three types of blood plasma formulations in two experiments. Identified proteins showed more than 50% overlap between plasma formulations. Detected proteins represented more than 100 canonical pathways, as was identified by pathway analysis. The major pathways and regulatory molecules were linked to inflammation.

Conclusion

Three types of plasma formulations were compared in two proteomic experiments. The most represented pathways, such as Acute Phase Response, Coagulation, or System of the Complement, had many proteins in common in both experiments. In both experiments plasma sample sets had the same direction of biochemical pathway changes: up- or down-regulation. The most represented biochemical pathways are linked to inflammation.

中文翻译：

---

富血小板和贫血小板血浆的蛋白质组学分析

背景

自体血液制品，例如富血小板血浆 (PRP) 是广泛用于加速损伤后组织愈合的商业产品。但其内容不规范，成分差异较大，可能导致临床疗效差异。此外，治疗效果的潜在分子机制尚不清楚。

目的

进行蛋白质组学研究以比较低白细胞 PRP、贫血小板血浆 (PPP) 和血浆的组成。对蛋白质组数据进行通路分析以评估分子水平上血浆制剂之间的差异。血浆中的低丰度调节蛋白以及由这些蛋白调节的细胞通路被鉴定和量化。

方法

使用多重同位素标记标签（TMT 标记）和无标记串联质谱法对血浆、低白细胞 PRP 和 PPP 进行定量蛋白质组学分析。血浆制剂来自两名献血者（每个实验一名献血者）。蛋白质组学数据的通路分析确定了制剂之间的主要差异。

结果

在两个实验中，在三种类型的血浆制剂中检测到近 600 种蛋白质。已鉴定的蛋白质在血浆制剂之间显示出超过 50% 的重叠。检测到的蛋白质代表了 100 多种规范途径，如通过途径分析确定的那样。主要途径和调节分子与炎症有关。

结论

在两个蛋白质组学实验中比较了三种类型的血浆制剂。最具代表性的途径，如急性期反应、凝血或补体系统，在两个实验中都有许多共同的蛋白质。在这两个实验中，血浆样品组具有相同的生化途径变化方向：上调或下调。最具代表性的生化途径与炎症有关。